Aims: Diagnosis of inflammatory bowel disease (IBD) is often associated with a diagnostic delay. Although faecal calprotectin is a helpful screening tool, the widespread use in primary care (PC) may not be appropriate due to the low prevalence of IBD in this setting. To increase pretest probability for a positive calprotectin test, an 8-item questionnaire (CalproQuest) was tested for its feasibility and acceptability in PC. Results: Of 95 patients with a complete CalproQuest 52 (54.7%) were positive, 39 (41.1%) fulfilled two major and 13 (13.7%) one major and greater than or equal to two minor criteria. Twenty-seven general practitioners completed 83 (87.4%) questionnaires on feasibility which was assessed positive. Eighty-two patients (86.3%) completed questionnaires on acceptance which was high.
| INTRODUCTION
Abdominal pain is one of the most frequent symptoms in primary care (PC). 1, 2 In the United States, where respective data have been collected, 2.5 million consultations due to abdominal pain were recorded per year. 3 General practitioners (GP) often face the diagnostic challenge of identifying patients in need for further diagnostics and differentiating patients with inflammatory bowel disease (IBD) from
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functional disorders such as irritable bowel syndrome (IBS). Crohn's disease (CD), ulcerative colitis (UC), and indeterminate colitis (IC) represent the three subtypes of IBD. 4 Estimated prevalence of IBD in the Swiss population is 205 cases per 100 000 (0.2%). 5 Meanwhile, the prevalence of IBS in Europe and North America is estimated at 10% to 15%. 6 Symptoms similar to IBS are frequently reported in patients before IBD is diagnosed. 7 Difficulties in recognizing early IBD, especially in PC, lead to considerable diagnostic delay in IBD, 4 which has been shown to be correlated with an increased risk of bowel stenosis and CD-related intestinal surgery. 8 The Data assessing the diagnostic accuracy of the calprotectin in the PC setting are scarce. In this setting, the pretest probability for a positive calprotectin is naturally low due to low prevalence of IBD. It is hence not astonishing that studies from PC indicate a questionable diagnostic accuracy. [22] [23] [24] [25] To increase pretest-probability for a positive calprotectin test and hence to increase its utility in the PC setting, an 8-item questionnaire (CalproQuest) was tested for its feasibility in PC.
2 | METHODS AND ANALYSIS 2.1 | Ethics, trial registration, informed consent, and funding
• Ethics: The study protocol was approved by the Ethics Committee of the Kanton Zurich (reference KEK-ZH-number 2013-0516).
• The study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki as reflected in a prior approval by the institution's human research committee.
• Trial registration number: ISRCTN66310845.
• Written, informed consent was obtained from each patient included in the study.
• 
| Study design
This study is a part of the prospective diagnostic ALERT trial (VAlidation of an 8-item questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in PC to reduce diagnostic delay in IBD), consisting of two independent parts A and B, conducted by gastroenterologists (A) and GPs (B). The details of the study design, including recruitment of patients and physicians, administration of patient records, informed consent, and confidentiality have been published previously. 26 Patients included in the study presented at their GP because of ongoing unspecific gastrointestinal symptoms for at least 2 weeks (abdominal pain, bloating, stool irregularities, diarrhoea).
The study design and including the study flow is shown in Figure 1 .
| Inclusion and exclusion criteria
Inclusion criteria:
• ≥18 years
• GP visit due to on-going unspecific gastrointestinal symptoms (abdominal pain, bloating, stool irregularities, diarrhoea) for at least 2 weeks
• No earlier diagnostic procedures (endoscopy) for the current episode
| Informed consent
Exclusion criteria:
• <18 years
• Known further/other abdominal pathologies as, eg, cancer
• Previous abdominal surgeries
• Treatment with steroids (topical and/or oral) and/or amino salicylates within 30 days prior inclusion into this study
• Endoscopic examination within 3 years prior screening 2.5 | Procedure (see also Figure 1 )
-Patients were subjected to CalproQuest.
-Patients obtained faecal samples to measure calprotectin levels.
Besides the possible diagnostic utility concerning the patient's complaints, the calprotectin was measured also in order to test for patient acceptance of stool sampling. No statement is possible concerning the validation of the CalproQuest with the calprotectin measures due to under powering.
-Patients completed the questionnaire on acceptance of stool sampling and physicians completed the questionnaire on feasibility of CalproQuest in daily practice.
-According to the current standard of care, patients with calprotectin levels ≥50 μg/g were referred to a gastroenterologist for endoscopic examination. It was at the discretion of the GP to follow this advice. The GP was informed about results of the endoscopy, and he forwarded these results to the study center.
| CalproQuest
CalproQuest is an 8-item IBD questionnaire consisting of four major and four minor questions specific for IBD ( Table 1 ). The CalproQuest is considered positive, if greater than or equal to two major criteria or one major criterion and two minor criteria are answered positively.
We assumed that a positive CalproQuest result might predict calprotectin levels ≥50 μg/g. Calprotectin levels above 50 μg/g are indicative for ongoing intestinal inflammation and call for further endoscopic examination.
| Faecal calprotectin
Faecal calprotectin levels were measured at the University Hospital and the bound complex is incubated with a development solution.
After stopping the reaction, the fluorescence in the reaction mixture is measured. The higher the response value, the more calprotectin is present in the specimen. To evaluate test results, the response for patient samples is compared directly with the response for calibrators.
| Questionnaires
The contents of the physician's questionnaire on feasibility and acceptance of CalproQuest in PC and the patient questionnaire on acceptance of stool sampling are provided within the Figures 2 and 3 .
| PRIMARY AND SECONDARY OUTCOMES
Primary outcome: Feasibility of CalproQuest in daily PC practice.
Secondary outcome: Patient-reported acceptance of stool sampling.
| Statistical analysis
Likert-bar plots visualize feasibility of the CalproQuest and the patient-reported acceptance. For the comparison of symptoms of Consort statement is shown in Figure 1 Since according to the study protocol, it was not mandatory for the GP to send patients with a positive Calprotectin to endoscopic evaluation, the data we received concerning endoscopic and histologic findings is far from complete. GPs sent the results of five endoscopies to the study center, of which four showed either no pathological findings or diverticulosis and/or polyps/adenomas, one showed evidence of CD. 
| DISCUSSION
Our study showed that the CalproQuest is a feasible instrument for the assessment of IBD in PC and that the patient reported acceptance of and understanding for stool sampling was high.
The rationale for the ALERT trial is the reduction of diagnostic delay in IBD patients. Since most patients present to their GP with unspecific abdominal complaints first, improving diagnostic procedures for diagnosing IBD patients in PC is one of the most important starting points to reduce diagnostic delay. However, following factors render the optimal diagnostic procedure extremely challenging in PC:
reasons of encounter for digestive disorders are common (5%-7%), 20, 21, 28, 29 but the prevalence of IBD extremely low (0.2%), 5 compared with a much higher prevalence of functional disorders (10%-15%). 6 In this low prevalence setting, pretest probability for positive diagnostic test results such as the calprotectin are naturally low.
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Since not all patients with unspecific gastrointestinal complaints can undergo invasive endoscopic examination, it is of utmost importance that other non-invasive diagnostic procedures are developed to reduce morbidity and mortality of a diagnostic delay in IBD. To increase pretest probability for a positive calprotectin test and hence to increase its utility in the PC setting, an 8-item questionnaire (CalproQuest) was tested for its feasibility in PC.
Very few studies currently exist to compare our findings. Danese et al published a 21-item questionnaire, which was developed by means of a systematic literature review in which CD specialists identified "red flags," ie, symptoms or sings suggestive of CD. 30 Healthy as well as known CD patients were subjected to the questionnaire and had to recall symptoms. The questionnaire was able to successfully discriminate functional disorders from CD. This questionnaire however was not yet prospectively validated and not tested for feasibility, which seems necessary considering large content compared with the 7 items of the CalproQuest.
Contradictory to findings from other studies, 31 our study population showed a high acceptance concerning stool sampling, probably due to good communication skills of the GPs in our study population.
The diagnostic strategy of combining a questionnaire with faecal sampling to measure calprotectin levels therefore seems feasible in the Swiss PC setting.
| Strengths and limitations
In the PC setting, this is one of the few existing studies on the noninvasive assessment of IBD, almost none of the former studies are prospective and most originate from secondary and tertiary care. 32 To our knowledge, the ALERT trial is the first attempt of prospectively developing a questionnaire for the assessment of IBD in PC.
According to the sample size calculation, targeted number of 80 patients assumed necessary for the feasibility testing in our study was more than achieved (n = 95). We abstained from restrictive inclusion criteria for the participation in the study. Therefore, patients represent the typical clientele with unspecific gastrointestinal complaints, which the GP is confronted with in daily practice. We therefore consider the study population to be repre- 
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